Results 71 to 80 of about 31,665,392 (202)

Benign by design: A paradigm shift in cosmetic ingredient development

open access: yesInternational Journal of Cosmetic Science, EarlyView.
Benign by design strategies enable the creation of biodegradable cosmetic ingredients, reducing environmental persistence while maintaining the intended biological activity. This work compiles design rules and tools to guide the development of more sustainable molecules for the cosmetics industry.
Sandra Mota   +3 more
wiley   +1 more source

3D-Pharma, A Ligand-based Virtual Screening tool using 3D Pharmacophore Fingerprints [PDF]

open access: yes
In this work, we introduced 3D-Pharma, a new Ligand-Based Virtual Screening method that uses fingerprints of pharmacophore triplets at atomic resolutions to build very simple and predictive models. Within 3D-Pharma the molecules are described by multiple
Julio CD, LOPES   +2 more
core   +1 more source

A Unified Hierarchical Multiscale Fusion Framework for Drug–Target Affinity Prediction: From Benchmark Performance to Nanomolar Inhibitor Discovery

open access: yesAdvanced Science, Volume 13, Issue 63, 12 November 2026.
A multimodal fusion framework integrating sequence, atomic, and fragment representations captures drug–target interactions across multiple scales. The model delivers strong predictive performance and enables efficient virtual screening. Applied to hematopoietic progenitor kinase 1 (HPK1), it identifies structurally diverse inhibitors with nanomolar ...
Shuo Liu   +7 more
wiley   +1 more source

Workflow illustration for pharmacophore-based 3D QSAR modeling and virtual screening to identify compounds with antagonistic activities against A2A.

open access: yes, 2019
Workflow illustration for pharmacophore-based 3D QSAR modeling and virtual screening to identify compounds with antagonistic activities against A2A.
Hisham K. Hamadeh (13317)   +3 more
core   +1 more source

Pharmacophore and Molecular Docking-Based Virtual Screening of B-Cell Lymphoma 2 (BCL 2) Inhibitor from Zinc Natural Database as Anti-Small Cell Lung Cancer [PDF]

open access: yes, 2020
Cancer is a disease involving genetic factors in its pathogenesis. The increase of cell survival as a result of genetic changes, which prevent apoptosis such as Bcl2 (B-cell lymphoma-2) activation, will cause the tumor to grow. The overexpression of Bcl2
Kharisma, Dina   +7 more
core   +1 more source

Pharmacophore Modeling and in Silico/in Vitro Screening for Human Cytochrome P450 11B1 and Cytochrome P450 11B2 Inhibitors

open access: yesFrontiers in Chemistry, 2017
Cortisol synthase (CYP11B1) is the main enzyme for the endogenous synthesis of cortisol and its inhibition is a potential way for the treatment of diseases associated with increased cortisol levels, such as Cushing's syndrome, metabolic diseases, and ...
Muhammad Akram   +5 more
doaj   +1 more source

Repurposing FDA‐Approved Drugs to Inhibit Fungal PPTases for Broad‐Spectrum Synergy

open access: yesAdvanced Science, Volume 13, Issue 63, 12 November 2026.
Fungal secondary metabolites serve as crucial virulence effectors; however, the potential of their biosynthetic pathways as antifungal targets remains inadequately comprehended. Repurposed FDA‐approved drugs inhibit fungal PPTase (essential for secondary metabolism) in vivo.
Zili Song   +7 more
wiley   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1477-1498, November 2026.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood   +7 more
wiley   +1 more source

Design of dual ligands using excessive pharmacophore query alignment : from 7th German Conference on Chemoinformatics: 25 CIC-Workshop Goslar, Germany, 6 - 8 November 2011 [PDF]

open access: yes, 2012
Dual- or multi-target ligands have gained increased attention in the past years due to several advantages, including more simple pharmacokinetic and phamarcodynamic properties compared to a combined application of several drugs.
Achenbach Janosch   +26 more
core   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy